Spironolactone has low selectivity for the MR vs. AR (~ threefold more selective for the MR vs. AR), which means it has greater potential to block ARs, which is associated with sexual side effects such as gynecomastia, especially at higher doses [36, 39–41]. This evidence concerns the gene NR3C2 and Gynecomastia.